The Medipattern Corporation

The Medipattern Corporation

December 20, 2011 06:30 ET

"Money on the Mark" Features Medipattern's Visualize:Vascular™

Radio Interview Concludes Visualize:Vascular™ Is a Valuable Tool for Cardiologists

TORONTO, ONTARIO--(Marketwire - Dec. 20, 2011) -

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical imaging software solutions that help medical practitioners to better understand lesions and critical anatomy, announced today that the Company was featured for a second time on the Money on the Mark radio program hosted by Dale Jackson in New York. The program can be downloaded from The interview focuses on use of Visualize:Vascular™ in a cardiology practice and their diagnostic services provider, Navix Diagnostix. Navix is one of Medipattern's channel partners.

"It [Visualize:Vascular™] can mean the difference between continued medical therapy and the patient going to a surgical revascularization or stenting," commented Dr. Robert Jumper, FACC, RVPI, Interventional Cardiologist with Cardiology of Fairfield County (CAFC), located in Connecticut. "It gives us a more complete picture and a better sense of the disease process in order to better treat the patient and get them to the appropriate course of therapy, whether it be continued preventive care and avoiding pre-mature surgery; or surgery and forgoing further preventive care."

Robert Kane, Senior Vice President of Clinical Services at Navix was interviewed in another segment where he commented, "It's sort of like radio and television. [Visualize:Vascular™] is like having a 3D TV as compared to what we did before was radio. 2D would be viewed as being flat. The vessel is a tube so it has 3 dimensions. We are able to see things with Medipattern that we have never been able to see before." Kane continued to comment regarding possible future applications for the technology, "We believe that there are many more applications for this: lower aorta, femoral artery and veins. Being able to see inside that vessel that is not functioning like it usually does is really a tremendous help. There are massive applications for this."

"Medipattern appreciates our early data collection work hosted by CAFC in support of developing our vascular product," commented Medipattern CEO Jeff Collins. "Medipattern is pleased to continue to foster our relationship with Navix. The two companies have recently included reciprocating web pages. Medipattern is seen on the Navix home page, and Navix's sub page, And Navix is seen on Medipattern's Solutions page Navix is in the process of proceeding with its planned product roll out for Visualize:Vascular™ including it within Navix's service offerings."

Upcoming Events

45th Annual Mid-Winter Leadership Conference MHA Jan 27, 2012 Framingham, MA
Annual Hospital - Physician Leadership Conference MHA Mar 16, 2012 Waltham, MA
Annual Meeting - MHA June 6 - 7, 2012 Brewster, MA
SVU/SVS Annual Conference June 7 - 9, 2012 Baltimore, MD

About Cardiology Associates of Fairfield County (CAFC):

The mission and vision of Cardiology Associates of Fairfield County, PC (CAFC) is to provide diagnostic testing and consultative care, in conjunction with primary healthcare providers, to patients throughout Fairfield County, Connecticut. It is the further mission and vision of CAFC to provide invasive and surgical cardiovascular techniques as well as expertise in cardiac-electrophysiology to patients. For more information, please visit the Company's website:

About Navix:

Since 1996, Navix has been dedicated to helping health care providers detect and diagnose cardiovascular disease. Navix partners with hospitals and physician practices to provide a full range of non-invasive heart & vascular diagnostic services, including vascular ultrasound, echocardiography, nuclear medicine and Holter monitoring. Navix's services include credentialed technologists, advanced, clinical protocols, lab accreditation (ICAVL, ICAEL & ICANL) consulting services, diagnostic equipment, risk-profiled stroke and vascular screening program, as well as other marketing programs to increase the number of patients referrals. Clinical oversight and testing interpretation services are provided by the client physician staff. For more information, please visit the Company's website:

About the Medipattern Corporation:

Medipattern® is a pioneer in the development of imaging software solutions that help medical practitioners to better understand lesions and critical anatomy. Medipattern uses its Cadenza™ technology to process images, finding the salient region of interest and presenting them in 2D and 3D formats that enhance the reader's perception. For more information, please visit the Company's website:

Medipattern® is a registered mark of The Medipattern Corporation. Visualize:Vascular™ is a trademark of the Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information